Last updated: February 19, 2026
This report provides a detailed analysis of Chilean patent application CL2017000979, focusing on its scope, asserted claims, and the broader patent landscape. The application, filed by CSL Limited, pertains to novel therapeutic agents.
What is the Core Innovation Protected by CL2017000979?
Patent application CL2017000979 protects novel polypeptide molecules and their therapeutic uses. Specifically, the invention concerns polypeptides exhibiting enhanced inhibitory activity against prothrombinase complex assembly. This complex is a critical component in the coagulation cascade, and its inhibition is a target for anticoagulant therapies.
The primary objective of the disclosed polypeptides is to reduce the risk of thrombosis and embolism. The patent describes polypeptides that bind to the cleavage site of Factor Xa, thereby preventing its activation by Factor VIIa and subsequent incorporation into the prothrombinase complex.
What Specific Claims Does CL2017000979 Assert?
The claims in CL2017000979 are structured to provide broad protection for the core invention and its applications. They encompass:
- Claim 1: A polypeptide having a specific amino acid sequence, characterized by its ability to inhibit the assembly of the prothrombinase complex. This claim defines the structural identity of the core inventive entity.
- Claim 2: A pharmaceutical composition comprising the polypeptide of Claim 1 and a pharmaceutically acceptable carrier. This extends protection to the formulation of the drug product.
- Claim 3: A method of treating or preventing a thrombotic or embolic disorder in a subject. This claim covers the therapeutic application of the polypeptide, outlining the medical conditions it is intended to address.
- Claim 4: The method of Claim 3, wherein the thrombotic or embolic disorder is selected from the group consisting of deep vein thrombosis, pulmonary embolism, arterial thrombosis, and stroke. This further specifies the targeted indications.
- Claim 5: The method of Claim 3, wherein the polypeptide is administered intravenously. This claim defines a specific route of administration.
- Claim 6: A kit for use in the treatment or prevention of a thrombotic or embolic disorder, comprising the polypeptide of Claim 1 and instructions for use. This claim covers the commercial packaging and delivery of the therapeutic.
The claims are designed to cover the active pharmaceutical ingredient itself, its formulated product, and its use in treating specific diseases, providing a comprehensive intellectual property shield.
What is the Scope of Protection for CL2017000979?
The scope of protection for CL2017000979 is defined by its claims and the underlying technical disclosures. The patent application focuses on a specific class of polypeptides engineered for enhanced prothrombinase inhibition. The protection extends to:
- Novel Polypeptide Sequences: The core of the invention lies in the specific amino acid sequences of the polypeptides claimed. These sequences are designed to confer superior anticoagulant properties compared to existing agents.
- Therapeutic Utility: The patent asserts the utility of these polypeptides in preventing and treating thrombotic and embolic events. This includes a range of vascular conditions.
- Pharmaceutical Compositions: Protection covers formulations containing the active polypeptide, ensuring that specific drug product designs are also covered.
- Methods of Treatment: The application claims the use of the polypeptide in medical treatment protocols for specified disorders.
The scope is focused on a targeted mechanism of action—inhibition of prothrombinase assembly—which differentiates it from broader anticoagulants targeting different points in the coagulation cascade.
What is the Status of CL2017000979?
Chilean patent application CL2017000979 was filed on March 17, 2017. As of the latest available information, the application is in the examination phase. The applicant, CSL Limited, is awaiting a decision from the National Institute of Industrial Property of Chile (INAPI) regarding patent grant. The examination process involves a thorough review of the application's novelty, inventive step, and industrial applicability against prior art.
Who is the Applicant and What is Their Position in the Market?
The applicant for CL2017000979 is CSL Limited, a global biotechnology company headquartered in Melbourne, Australia. CSL is a major player in the biopharmaceutical industry, with a focus on developing and manufacturing plasma-derived and recombinant protein therapies. The company has a significant presence in the area of hematology and critical care, which includes a portfolio of anticoagulant and hemostatic products.
CSL's market position is characterized by its expertise in complex protein therapeutics and its established research and development capabilities. The company has a history of bringing innovative treatments to market, particularly for rare and serious diseases. The pursuit of patents for novel anticoagulants aligns with its strategic focus on expanding its therapeutic offerings in areas where unmet medical needs exist.
What is the Competitive Landscape for Anticoagulant Therapies in Chile?
The anticoagulant market in Chile, as globally, is highly competitive, featuring a range of established and emerging therapeutic classes. Key players and product types include:
- Vitamin K Antagonists (VKAs): Warfarin remains a widely used VKA. While effective, VKAs require regular monitoring due to their narrow therapeutic window and numerous drug/food interactions.
- Direct Oral Anticoagulants (DOACs): This class includes direct thrombin inhibitors (e.g., dabigatran) and Factor Xa inhibitors (e.g., rivaroxaban, apixaban, edoxaban). DOACs offer advantages such as predictable pharmacokinetics, less frequent monitoring, and fewer interactions, leading to their increasing market share.
- Parenteral Anticoagulants:
- Unfractionated Heparin (UFH): A cornerstone for acute management of thrombotic events.
- Low Molecular Weight Heparins (LMWHs): (e.g., enoxaparin, dalteparin) Offer more predictable pharmacokinetics than UFH and are widely used for both treatment and prophylaxis.
- Synthetic Pentasaccharides: (e.g., fondaparinux) Another class of parenteral anticoagulants.
- Antiplatelet Agents: While distinct from anticoagulants, they compete for indications where thrombosis is a concern (e.g., aspirin, clopidogrel).
The competitive landscape is characterized by:
- Established Generic Penetration: For older anticoagulants like warfarin and unfractionated heparin, generic versions are widely available, driving down costs.
- Patent Expirations of Blockbuster DOACs: Several key DOACs have seen or are approaching patent expirations in major markets, which will lead to increased generic competition.
- Focus on Novel Mechanisms: Ongoing research and development efforts are directed towards anticoagulants with improved safety profiles (reduced bleeding risk), more targeted actions, and novel delivery methods.
- Therapeutic Area Specialization: Companies often specialize in specific niches within anticoagulation, such as for patients with specific comorbidities or undergoing particular medical procedures.
CSL's potential new anticoagulant, if patented and approved, would enter this dynamic market. Its success would depend on demonstrating clear advantages in efficacy, safety, or convenience over existing options, particularly the leading DOACs and LMWHs.
What is the Patent Landscape for Prothrombinase Inhibitors?
The patent landscape for prothrombinase inhibitors is active and evolving, reflecting the ongoing interest in targeting this pathway for antithrombotic therapy. Key aspects include:
- Broad Structural Claims: Patents in this area often claim broad classes of molecules designed to inhibit the prothrombinase complex. This includes antibodies, small molecules, and modified peptides.
- Specific Amino Acid Sequences: For polypeptide-based inhibitors like those in CL2017000979, patents will detail specific amino acid sequences that confer the desired inhibitory activity and pharmacokinetic properties.
- Methods of Use Claims: Patents typically include claims covering the use of these inhibitors for treating or preventing various thrombotic conditions, such as deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and myocardial infarction.
- Formulation and Delivery: Claims may also extend to specific pharmaceutical formulations, dosages, and administration methods designed to optimize efficacy and patient compliance.
- Combination Therapies: Research and patent filings may also explore the use of prothrombinase inhibitors in combination with other anticoagulants or antiplatelet agents to achieve synergistic effects.
Major pharmaceutical and biotechnology companies are active in this space. For instance, companies developing Factor Xa inhibitors and direct thrombin inhibitors have significant patent portfolios. CSL's application CL2017000979 suggests an effort to secure intellectual property for a distinct class of prothrombinase inhibitors, potentially offering a unique mechanism or improved profile. The novelty of the polypeptide sequences and their specific inhibitory mechanism are critical for differentiating these patents from existing prior art.
What Prior Art is Relevant to CL2017000979?
The patentability of CL2017000979 hinges on its ability to demonstrate novelty and an inventive step over existing knowledge. Relevant prior art would include:
- Published scientific literature: Research papers detailing studies on the coagulation cascade, prothrombinase complex, and attempts to inhibit its assembly using various molecular entities.
- Existing patents: Other patent applications and granted patents related to anticoagulant agents, particularly those targeting Factor Xa, prothrombin, or other components of the prothrombinase complex. This includes patents for LMWHs, fondaparinux, and Factor Xa inhibitors like rivaroxaban and apixaban, as well as earlier hirudin-based inhibitors and experimental antibodies.
- Known therapeutic agents: Approved anticoagulant drugs in Chile and globally, which represent the state of the art against which a new invention must demonstrate improvement.
The specific amino acid sequences disclosed in CL2017000979 would be compared against known polypeptide sequences, and their inhibitory activity against prothrombinase complex assembly would be evaluated against the known efficacy of existing anticoagulants. The inventive step would be established if the claimed polypeptides exhibit a surprising or unexpected improvement in properties like potency, selectivity, safety profile (e.g., reduced bleeding risk), or pharmacokinetic characteristics.
What are the Potential R&D and Investment Implications?
The analysis of CL2017000979 has several implications for R&D and investment decisions:
- Therapeutic Innovation: The application signals CSL Limited's commitment to developing novel anticoagulants targeting a specific point in the coagulation cascade. If granted, this patent could represent a new class of antithrombotic agents, potentially addressing limitations of current therapies.
- Market Entry Potential: A granted patent would provide CSL with a period of market exclusivity in Chile, allowing for potential commercialization. This could lead to significant revenue generation if the drug proves clinically and commercially successful.
- Competitive Positioning: The success of this patent and subsequent drug development could alter the competitive dynamics in the Chilean anticoagulant market, potentially challenging existing market leaders.
- Investment Opportunity/Risk: For investors, this patent application represents both an opportunity and a risk.
- Opportunity: If the patent is granted and the therapeutic is successful, it could offer substantial returns.
- Risk: Patent prosecution is uncertain, and the development of pharmaceuticals is inherently high-risk, high-cost, and lengthy. Clinical trial failures or regulatory hurdles could render the patent and investment worthless.
- Licensing and Collaboration: The patent could also create opportunities for licensing agreements or strategic partnerships, allowing other companies to develop or market the technology in exchange for royalties or upfront payments.
- R&D Strategy: Competitors may need to assess their own R&D pipelines to ensure they are not infringing on CSL's potential patent rights and to identify areas where they can differentiate their offerings or develop alternative mechanisms of action.
Key Takeaways
Chilean patent application CL2017000979, filed by CSL Limited, seeks protection for novel polypeptides designed to inhibit the prothrombinase complex, a critical target for anticoagulant therapies. The claims cover the polypeptide molecules, pharmaceutical compositions, and methods of treating thrombotic or embolic disorders. The application is currently under examination by INAPI. CSL Limited is a significant player in the biopharmaceutical market, particularly in plasma-derived and recombinant therapies. The Chilean anticoagulant market is competitive, featuring VKAs, DOACs, and various parenteral agents. The patent landscape for prothrombinase inhibitors is active, with ongoing efforts to develop novel agents with improved safety and efficacy profiles. The successful grant and subsequent commercialization of a patent for these novel polypeptides could represent a significant R&D and investment opportunity, potentially reshaping the competitive landscape in Chile.
Frequently Asked Questions
-
What is the primary mechanism of action for the polypeptides disclosed in CL2017000979?
The polypeptides are designed to inhibit the assembly of the prothrombinase complex by binding to the cleavage site of Factor Xa.
-
When was Chilean patent application CL2017000979 filed?
The application was filed on March 17, 2017.
-
What types of thrombotic or embolic disorders are specifically mentioned in the claims?
The claims mention deep vein thrombosis, pulmonary embolism, arterial thrombosis, and stroke.
-
Besides the active ingredient, what else does the patent application claim?
The application also claims pharmaceutical compositions containing the polypeptide and kits for use in treatment or prevention.
-
What is the current status of CL2017000979?
The application is currently in the examination phase with the National Institute of Industrial Property of Chile (INAPI).
Citations
[1] CSL Limited. (2017). Chilean Patent Application CL2017000979. National Institute of Industrial Property of Chile (INAPI).
